GGrantIndex
← Search

Genotyping and Sequencing

$193,036P30FY2009CANIH

Ohio State University, Columbus OH

Investigators

Linked publications, trials & patents

Trial NCT04662645Trial NCT04602026Trial NCT04567706Trial NCT04454086Trial NCT04439006Trial NCT04329962Trial NCT04269837Trial NCT04267874Trial NCT04233567Trial NCT04229381Trial NCT04220684Trial NCT04205903Trial NCT04205240Trial NCT04205071Trial NCT04164069Trial NCT04140513Trial NCT04120454Trial NCT04116970Trial NCT04115163Trial NCT04063410Trial NCT04049539Trial NCT04032106Trial NCT03975231Trial NCT03943342Trial NCT03892044Trial NCT03868423Trial NCT03858855Trial NCT03824327Trial NCT03798639Trial NCT03786354Trial NCT03749018Trial NCT03728361Trial NCT03719092Trial NCT03715959Trial NCT03711890Trial NCT03691350Trial NCT03665675Trial NCT03656835Trial NCT03654638Trial NCT03631641Trial NCT03611205Trial NCT03583424Trial NCT03568526Trial NCT03537599Trial NCT03532581Trial NCT03525925Trial NCT03513562Trial NCT03463460Trial NCT03460483Trial NCT03447808Trial NCT03409432Trial NCT03372720Trial NCT03333746Trial NCT03328936Trial NCT03307044Trial NCT03287453Trial NCT02960100Trial NCT02950220Trial NCT02942524Trial NCT02940301Trial NCT02927899Trial NCT02835755Trial NCT02831582Trial NCT02812693Trial NCT02795104Trial NCT02791737Trial NCT02760030Trial NCT02439255Trial NCT02303392Trial NCT02101944Trial NCT02015117Trial NCT01964924Trial NCT01955499Trial NCT01861314Trial NCT01841723Trial NCT01811212Trial NCT01533194Trial NCT01519414Trial NCT01515176Trial NCT01468896Trial NCT01425879Trial NCT01351896Trial NCT01281124Trial NCT01280058Trial NCT01254617Trial NCT01254578Trial NCT01251874Trial NCT01249430Trial NCT01238133Trial NCT01132586Trial NCT01130506Trial NCT01129193Trial NCT01126502Trial NCT01076556Trial NCT01017640Trial NCT00735930Trial NCT00703300Trial NCT00602277Trial NCT00563290Trial NCT00499473

Abstract

The OSUCCC Genotyping and Sequencing Shared Resource (GSSR) - first established in 1997 as a restricted developing shared resource - has rapidly evolved into a state-of-the art DNA analysis facility providing an essential service available to and requested by the OSUCCC membership. The GSSR has demonstrated ability to handle large sequencing volumes, maintain high service quality, and accommodate a steadily increasing number of users. The GSSR has leveraged strong institutional support and user fees totaling $4.4 M to provide sequencing and genotyping performed by highly experienced personnel with outstanding quality control. The GSSR is located on the fourth floor of the Tzagournis Medical Research Facility with three other CCC SRs. The GSSR has one 48 capillary Applied Biosystems 3730 DNA Analyzer, one 96 capillary ABI PRISM[unreadable] 3700 DNA Analyzer (to be replaced by an ABI 3730 in early 2004) and ancillary equipment for DNA sequencing and genotyping preparation. Now as a full SR, the GSSR has assumed a leading role in supporting molecular cancer research with state-of-the-art equipment, as well as developing novel methodologies that will become essential tools in the coming years for our membership. Specific goals for the sequencing and genotyping core are: (1) To provide affordable, high-throughput, high-quality genotyping and sequencing services in a timely manner. Genotyping will include screening methods for finding new polymorphisms (such as DHPLC) and scoring known polymorphisms. (2) To develop novel methodologies and applications relevant to cancer research, including genome-wide analys s of DNA methylation, gene silencing, and gene dosage, and large-scale genotyping panels (including haplotyping) targeted to cancer biology and therapeutics. (3) To train researchers and students in software utilization, data interpretation, and experimental strategies, conduct trouble shooting meetings with laboratory groups, and assist in the preparation of materials for publication. In the past year, usage of GSSR has increased 12% with now nearly 40 members from 3 CCC programs using the facility. The GSSR work has supported over 350 peer-reviewed publications (excluding reviews) since the last competitive renewal. Of these, 67 (19%) were in the 17 journals ranked highest by citation index (10-29.6). Building on this solid foundation, the task of the OSUCCC GSSR is to be an outstanding resource in the application of DNA analysis, in an era of rapid and profound technological advances.

View original record on NIH RePORTER →